A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter.

Trial Profile

A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2016 This trial is prematurely ended in Portugal (end date: 10 May 2009), Sweden, Netherlands (end date: 10 May 2009), United kingdom and completed in Italy.
    • 02 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top